Nova Patents
PL2811981T3

Improved adjuvant formulations comprising tlr4 agonists and methods of using the same

Abstract

This record has no abstract on file.

Term

6.4 yearsto projected expiry

Projected expiry 7 February 2033, counted from filing; an application has no term until it is granted.

  1. Priority
  2. Filed
  3. Published
  4. Today
  5. Projected expiry

24 members in 15 offices

This recordMember, by publication datePriority claim5 more offices are in the list below

Priority claims10

Priority claims
DocumentOfficeKindDate
201261596066United States of AmericaP
201261596066United States of AmericaP
13746983European Patent Office (EPO)A
2013025204United States of AmericaW
2013025204United States of AmericaW
137469839–––
201261596066P–––
EP20130746983–––
US201261596066P–––
WO2013US25204–––

Members24

Family members, oldest first
DocumentOfficeKind
WO2013119856A1World Intellectual Property Organization (WIPO)A1
EP2811981A1European Patent Office (EPO)A1
US2015017191A1United States of AmericaA1
CN104363892AChinaA
EP2811981A4European Patent Office (EPO)A4
ZA201805284A0South AfricaA0
ZA201405890BSouth AfricaB
EP2811981B1European Patent Office (EPO)B1
LT2811981TLithuaniaT
DK2811981T3DenmarkT3
PT2811981TPortugalT
TR2019008003T4TürkiyeT4
TR201908003T4TürkiyeT4
HRP20190960T1CroatiaT1
RS58868B1SerbiaB1
SI2811981T1SloveniaT1
PL2811981T3This recordPolandT3
CN110339160AChinaA
EP3563834A1European Patent Office (EPO)A1
ES2729967T3SpainT3
HUE044841T2HungaryT2
ZA201805284BSouth AfricaB
US11510875B2United States of AmericaB2
US2023116042A1United States of AmericaA1